

Angelini Pharma

Thursday, March 23, 2023
14:00 - 15:00, Lecture Hall 103

Which ion channel? Precision medicine in treatment of epilepsy: from autoimmune encephalitis to Dravet

Nico Melzer and Konstantin Makridis, Duesseldorf and Berlin

The bedrock of accurate management of any disease is precision medicine; tailoring the treatment to that of a specific individual taking into account the genes, environment, lifestyle and the presenting condition. In this symposium, we take a look at two subtypes of epilepsy known to be drug resistant: autoimmune-induced encephalitis/epilepsies, and specific variants of the Dravet syndrome. In terms of seizure suppression and autoimmune encephalitis management, is there a correlation between the mechanism of action for Cenobamate and anti-inflammatory properties at the pathogenetic level? Likewise, could there be exceptions to the longstanding guideline of ruling out sodium channel blockers (SCBs) in any case of Dravet syndrome? Are there variants of this syndrome where SCBs could be efficacious?

These questions will be discussed extensively at this symposium featuring two speakers: PD Dr. Nico Melzer, a Senior Neurologist at the University Clinic in Duesseldorf and a specialist in autoimmune encephalitis with several publications in this topic, and Dr. Konstantin Makridis, a neuropediatrician at the Charite University Clinic Berlin with special interests in epilepsy, genetics and novel treatments.

- 14:00 **Welcome - Nico Melzer, Duesseldorf**
The importance of the persistence current in the treatment of epilepsy and inflammation
- 14:05 Nico Melzer, Duesseldorf
Seizure and immunosuppressive spectrum of action of cenobamate in autoimmune encephalitis with focal seizures
- 14:25 Konstantin Makridis, Berlin
The mechanism of action of cenobamate in LoF-Dravet variants - When are sodium channel blockers indicated or contraindicated?
- 14:45 **Questions | Discussion**
- 14:55 **Closing Remarks -**
Nico Melzer, Duesseldorf



**Angelini
Pharma**